The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides

Journal of Leukocyte Biology

Volumn 68, Issue 4, 2000, Pages 455-463

  Weiner, G J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Allergic diseases; Antigen presenting cells; Asthma; B cells; Natural killer cells

Indexed keywords

BACTERIAL DNA; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; OLIGODEOXYNUCLEOTIDE;

ALLERGIC DISEASE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ASTHMA; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CPG ISLAND; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HUMAN; IMMUNIZATION; IMMUNOSTIMULATION; INFECTION; LEUKOCYTE ACTIVATION; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMAL; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS; CPG ISLANDS; DNA, BACTERIAL; DRUG EVALUATION, PRECLINICAL; HUMAN; HYPERSENSITIVITY; IMMUNIZATION; LYMPHOCYTE ACTIVATION; LYMPHOKINES; MACROPHAGE ACTIVATION; MICE; MODELS, ANIMAL; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; REACTIVE OXYGEN SPECIES; SPECIES SPECIFICITY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTE SUBSETS;

EID: 0033779762     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases
2. Treatment of inoperable malignant tumors with the toxins of erysipelas and the bacillus prodigiosus
3. Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
4. In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG
5. DNA from bacteria, but not vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth
6. Simulation of in vitro murine lymphocyte proliferation by bacterial DNA
7. CpG motifs in bacterial DNA trigger direct B-cell activation
8. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
9. CpG islands as gene markers in the vertebrate nucleus
10. Adjuvant immunotherapy in superficial bladder cancer
11. In vitro augmentation of natural killer cell activity and production of interferonalpha/beta and gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG
12. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides [editorial]
13. Responses of human B cells to DNA and phosphorothioate oligodeoxynucleotides
14. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation
15. Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: A comparative study
16. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds
17. Rapid immune activation by CpG motifs in bacterial DNA Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway
18. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA
19. Macrophages ingest and are activated by bacterial DNA
20. A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-Kappa B p65 causes sequence-specific immune stimulation
21. Positive and negative regulatory elements contribute to CpG oligonucleotide-mediated regulation of human IL-6 gene expression
22. Mechanism of action of CpG DNA
23. Signal transduction pathways activated by CpG-DNA
24. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of C-myc and Bcl-xL
25. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells Costimulation with IL-2 results in a highly immunogenic phenotype
26. Imnmnostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells
27. Macrophage activation by immunostimutatory DNA
28. IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides
29. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines
30. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA
31. Immunostimulatory CpG oligodeoxynacleotides enhance the immune response to vaccine strategies involving granulocytemacrophage colony-stimulating factor
32. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
33. Induction of NK activity in routine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
34. Bacterial DNA-induced NK cell IFN-gamma production is macrophage secretion of IL-12
35. Role of type I interferons in T cell activation induced by CpG DNA
36. CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells
37. CpG DNA co-stimulates antigen-reactive T cells
38. Hematopoietlc remodeling triggered by CpG DNA
39. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
40. Bacterial DNA induces NK cells to produce 1FN-gamma in vivo and increases the toxicity of lipopolysaccharides
41. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs
42. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
43. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides
44. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
45. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
46. Multivalent cross-linking of membrane Ig sensitizes murine B cells to a broader spectrum of CpG-containing oligodeoxynucleotide motifs, including their methylated counterparts, for stimulation of proliferation and Ig secretion
47. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge
48. Ganglioside vaccines with emphasis on GM2
49. Effective adjuvants for the induction of antigen-specific delayed type hypersensitivity
50. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long term results of a clinical trial
51. Antimetastatic activity induced by Clostridium butyricum and characterization of effector cells
52. Effect of cell wall skeleton and monophosphoryl lipid a adjuvant on the immunogenicity of a murine B16 melanoma vaccine
53. Active specific immunization in the treatment of patients with melanoma
54. CpG DNA switches on Th1 immunity and modulates antigen-presenting cell function
55. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
56. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants
57. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
58. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans
59. Immunotherapy of cancer with dendritic-cell-based vaccines
60. Dendritic cell based therapy of cancer
61. Dendritic cells hold promise for immunotherapy
62. From dendritic cells to tumonr vaccines
63. Immunotherapy using dendritic cells picks up steam
64. Dendritic cells and immune-based therapies
65. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
66. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma
67. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells
68. Modulating the immune response to genetic immunization
69. DNA vaccination for cancer treatment
70. Toward the development of DNA vaccines
71. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells
72. Priming of cytotoxic T lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes
73. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
74. Contribution of Cpg motifs to the immunogenicity of DNA vaccines
75. Effects of CpG DNA on Th1/Th2 balance in asthma
76. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
77. Conjugation of immunostimulatory DNA to the short ragweed allergen Arab a 1 enhances its immunogenicity and reduces its allergenicity
78. CpG DNA: A pathogenic factor in systemic lupus erythematosus?
79. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA
80. Do DNA vaccines induce autoimmune disease?
81. Microbial products induce autoimmune disease by an IL-12-dependent pathway
82. Cytokine combinations in immuno-therapy for solid tumors - A review
83. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy
84. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
85. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12
86. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model
87. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice
88. Idec-C2b8 (Rituximab) anti-Cd20 monoclonal antibody therapy patients with relapsed low-grade non-Hodgkins lymphoma
89. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
90. Immunostimulatory oligodoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma
91. Immunotherapy of cancer with genetically modified tumor vaccines
92. Cancer vaccines - Challenges and potential solutions
93. A new foreign policy: MHC class I molecules monitor the outside world